Armata Pharmaceuticals, Inc. (ARMP) Misses Q4 EPS by 7c

Armata Pharmaceuticals, Inc. (NYSE: ARMP) reported Q4 EPS of ($0.29), $0.07 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $1.05 million versus the consensus estimate of $1.67 million.

For earnings history and earnings-related data on Armata Pharmaceuticals, Inc. (ARMP) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• FDA approves Padcev plus Keytruda for muscle-invasive bladder cancer
• UBS Reiterates Buy Rating on Dollar Tree (DLTR)